---
title: "Voyager Therapeutics reports favorable GLP tox and durable CNS tau lowering for VY1706 ahead of clinical dosing"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292492049.md"
description: "Voyager Therapeutics reported favorable GLP toxicology and durable CNS tau reduction for VY1706. Preclinical data showed no adverse findings in non-human primates up to 5 x 10^13 vg/kg, with up to 75% MAPT mRNA and tau protein lowering sustained for six months. The FDA cleared the IND in June 2026, with a multi-site dose-escalation trial planned for H2 2026."
datetime: "2026-07-13T12:53:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292492049.md)
  - [en](https://longbridge.com/en/news/292492049.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292492049.md)
generator: "portal-rs"
---

# Voyager Therapeutics reports favorable GLP tox and durable CNS tau lowering for VY1706 ahead of clinical dosing

**Voyager Therapeutics presented GLP toxicology data showing favorable tolerability and up to 75% MAPT mRNA and tau protein reduction with VY1706.**

**Key Highlights:**

-   Three- and six-month GLP tox in non-human primates showed no adverse CNS, dorsal root ganglia or peripheral organ findings up to 5 x 10^13 vg/kg.
-   Single IV dose achieved broad, durable, dose-dependent CNS delivery with up to 75% lowering of MAPT mRNA and tau protein through six months.
-   ALPL identified as a mediator of VY1706 blood-brain barrier transport, supporting potential cross-species translatability.
-   FDA cleared an IND for VY1706 in June 2026; dosing in a multi-site, open-label, dose-escalation trial planned in H2 2026.

Original SEC Filing: Voyager Therapeutics, Inc. \[ VYGR \] - 8-K - Jul. 13, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [VYGR.US](https://longbridge.com/en/quote/VYGR.US.md)

## Related News & Research

- [Voyager Therapeutics advances tau-silencing gene therapy program](https://longbridge.com/en/news/292519601.md)
- [Gentian Diagnostics to attend PReS meeting, spotlight circulating calprotectin testing in pediatric rheumatology](https://longbridge.com/en/news/297638164.md)
- [GSK to advance mRNA flu vaccine to late-stage trial](https://longbridge.com/en/news/297605972.md)
- [Global Partners (GLP) Stock Still Looks Inexpensive On Earnings And Cash Flow](https://longbridge.com/en/news/297245286.md)
- [Fortrea to buy Worldwide Clinical Trials early-phase services unit for $45M all-cash](https://longbridge.com/en/news/297773693.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**